Cover Image
市場調查報告書

瘦素(Leptin)受體:開發中產品分析

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365778
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
瘦素(Leptin)受體:開發中產品分析 Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 50 Pages
簡介

本報告提供以瘦素(Leptin)受體為標的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

瘦素(Leptin)受體 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 開發中的產品:各企業

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • ConSynance Therapeutics Inc
  • Jyant Technologies Inc
  • NeuroNano Pharma Inc
  • Neurotez Inc
  • Novelion Therapeutics Inc
  • XL-protein GmbH

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0942TDB

Summary:

According to the recently published report 'Leptin Receptor - Pipeline Review, H2 2017'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

The report 'Leptin Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration and Preclinical stages are 1 and 7 respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Oncology which include indications Obesity, Alzheimer's Disease, Lipodystrophy, Type 2 Diabetes, Acquired Generalized Lipodystrophy (Lawrence Syndrome), Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome), Breast Cancer, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome) and Type 1 Diabetes (Juvenile Diabetes).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
  • The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview
    • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development
    • ConSynance Therapeutics Inc
    • Jyant Technologies Inc
    • NeuroNano Pharma Inc
    • Neurotez Inc
    • Novelion Therapeutics Inc
    • XL-protein GmbH
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles
    • CV-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • memtin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metreleptin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Agonize Leptin Receptor for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Agonize Leptin Receptor for Metabolic Disorders and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XL-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products
  • Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 12, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
      • May 05, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
      • Apr 04, 2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
      • Mar 30, 2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
      • Jan 23, 2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency
      • Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy
      • Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease
      • Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin
      • Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin
      • May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy
      • Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy
      • Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer's Disease
      • Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy
      • Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy
      • Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by ConSynance Therapeutics Inc, H2 2017
  • Pipeline by Jyant Technologies Inc, H2 2017
  • Pipeline by NeuroNano Pharma Inc, H2 2017
  • Pipeline by Neurotez Inc, H2 2017
  • Pipeline by Novelion Therapeutics Inc, H2 2017
  • Pipeline by XL-protein GmbH, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top